September 29, 2014 11:30 a.m. ET
Update: FINRA/NYSE TRF Technical Issue
FINRA/NYSE TRF customers are advised that the previous issue affecting reports to UTDF/CTS has been resolved. All systems are operating normally at this time. All trades that were not reported in a timely fashion by the TRF will be submitted to the tape.
Posted: September 29, 2014
FINRA/NYSE TRF Experiencing Technical Problems
FINRA/NYSE TRF is currently experiencing difficulties reporting executions to UTDF/CTS. Customers with technical alternatives should consider the extent to which they should route to another FINRA TRF to comply with OTC reporting obligations. New announcements will be made when updates are available.
Posted: August 25, 2014
Holiday Reminder Regarding TRF Market Data
In observation of Labor Day, the TRF Systems will be closed on Monday, September 1, 2014. As stated in the data feed interface specifications, FINRA may send out unmarked test data via its data feeds on market holidays. Direct data feed subscribers, including recipients of TRF data, should take the necessary precautions to prevent data corruption. Please contact FINRA Operations at (866) 776-0800 if you have any questions.
Posted: August 15, 2014
Trading of Vascular Biogenics Ltd.
Member firms that engaged in trading of Vascular Biogenics Ltd. (VBLX) from July 31, 2014, to August 7, 2014, should be aware that all trades in VBLX issues have been reversed and removed from the consolidated tape systems. Therefore, no additional action is required from firms to resolve any transactions on the tape in this security. Please direct questions concerning this notice via email to FINRA Product Management or call (866) 899-2107.
Posted: August 8, 2014
Trades in Vascular Biogenics
Member firms that engaged in trading of Vascular Biogenics Ltd. (VBLX) from July 31, 2014, to August 7, 2014, are advised to refer to the following NASDAQ OMX Regulatory Message. FINRA member firms should take no corrective action at this time with regard to prior trades in VBLX. FINRA will provide additional guidance regarding any required processing.